文献速递神经肿瘤

超越荧光引导切除:基于5-ALA的胶质母细胞瘤治疗

Beyond fluorescence-guided resection: 5-ALA-based glioblastoma therapies.
PubMed 文献 · Acta Neurochir (Wien) · 2024-04-02

胶质母细胞瘤是最常见的原发性恶性脑肿瘤,尽管多模式治疗不断进步,预后仍差。标准治疗为最大安全范围显微手术切除后辅以替莫唑胺放化疗。本综述总结了以5-ALA诱导肿瘤内敏化卟啉为基础的局部治疗(如光动力、声动力和放射动力治疗)作为当前标准治疗辅助手段的现状,这些治疗通过生成活性氧诱导细胞死亡,已有初步临床试验数据。

要点

  • 胶质母细胞瘤标准治疗为最大安全切除后替莫唑胺放化疗。
  • 5-ALA可在肿瘤组织内诱导敏化卟啉形成。
  • 光动力、声动力和放射动力治疗通过活性氧诱导细胞死亡,已有初步临床试验数据。

核心结论

  • 本综述旨在总结基于5-ALA的局部治疗(光动力、声动力和放射动力治疗)作为胶质母细胞瘤当前标准治疗辅助手段的现状。

研究设计与样本

  • 综述,总结基于5-ALA的光动力治疗、声动力治疗和放射动力治疗作为胶质母细胞瘤标准治疗辅助手段的现状。

主要发现

  • 外部刺激响应性治疗如光动力治疗、声动力治疗和放射动力治疗可在给予5-ALA后通过生成活性氧诱导细胞死亡机制。
  • 5-ALA可诱导肿瘤组织内敏化卟啉的形成。
  • 已有来自临床试验的初步数据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma is the most common primary malignant brain tumor. Despite advances in multimodal concepts over the last decades, prognosis remains poor. Treatment of patients with glioblastoma remains a considerable challenge due to the infiltrative nature of the tumor, rapid growth rates, and tumor heterogeneity. Standard therapy consists of maximally safe microsurgical resection followed by adjuvant radio- and chemotherapy with temozolomide. In recent years, local therapies have been extensively investigated in experimental as well as translational levels. External stimuli-responsive therapies such as Photodynamic Therapy (PDT), Sonodynamic Therapy (SDT) and Radiodynamic Therapy (RDT) can induce cell death mechanisms via generation of reactive oxygen species (ROS) after administration of five-aminolevulinic acid (5-ALA), which induces the formation of sensitizing porphyrins within tumor tissue. Preliminary data from clinical trials are available. The aim of this review is to summarize the status of such therapeutic approaches as an adjunct to current standard therapy in glioblastoma.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Stummer W, Müther M, Spille D, et al. Beyond fluorescence-guided resection: 5-ALA-based glioblastoma therapies. Acta Neurochir (Wien). 2024. PMID: 38563988. doi:10.1007/s00701-024-06049-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。